VictoryShares US Discovery Enhanced Volatility Wtd ETF
Limited financial coverage for CSF.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Price Chart
About the company
The VictoryShares US Discovery Enhanced Volatility Wtd ETF endeavors to match the investment returns of the Nasdaq VictoryUS Small Cap 500 Long/Cash Volatility Weighted Index (known as the "Long/Cash Index"), excluding any charges for fees and expenses. Its distinct Volatility Weighting Methodology incorporates both fundamental criteria and volatility as factors in an attempt to surpass the performance of conventional market capitalization-weighted indexing strategies. The underlying Long/Cash Index actively manages market risk by strategically decreasing its equity market involvement during severe downturns, then re-entering when asset prices have either fallen further or recovered.
- IPO
- 2014
- HQ
- San Antonio, TX, US
Get TickerSpark's AI analysis on CSF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- 52W High
- $60.63
- 52W Low
- $47.72
- 50D MA
- $53.47
- 200D MA
- $54.26
- Beta
- 0.59
- RSI (14)
- 45
- Avg Volume
- 6.42K
No earnings-call transcripts are available for CSF yet.
- Free Float
- 0.0%
- Shares Outstanding
- 602.07K
- Float Shares
- 0
of shares held by institutions
19 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Raymond James Financial Services Advisors, Inc. | 99.12K | ▼ 5.65K |
| Cetera Advisor Networks LLC | 40.53K | ▲ 2.68K |
Our CSF coverage
Recent articles, reports, and earnings notes.
No research on CSF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CSF report →Chime Scholars Foundation Announces 2026–2027 Cohort
businesswire.com · Aug 12
Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform
globenewswire.com · Jul 16
Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease
gurufocus.com · Jul 14
Plus Therapeutics gains CAP accreditation for CNSide CSF assay platform
proactiveinvestors.com · Jun 4
Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption
globenewswire.com · Apr 7
Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives
globenewswire.com · Apr 2
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026
globenewswire.com · Mar 18
Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA
globenewswire.com · Feb 25
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.